HC Wainwright Brokers Decrease Earnings Estimates for RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for Arcus Biosciences in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.19) per share for the quarter, down from their prior forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.04) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.30) EPS, FY2028 earnings at ($2.83) EPS and FY2029 earnings at ($1.63) EPS.

A number of other equities research analysts also recently weighed in on the company. Bank of America dropped their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Arcus Biosciences in a research report on Wednesday. Morgan Stanley reduced their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday. Wells Fargo & Company cut their price objective on shares of Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, The Goldman Sachs Group reduced their price objective on shares of Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.67.

Arcus Biosciences Stock Down 2.9 %

NYSE:RCUS opened at $8.28 on Friday. The company has a market cap of $876.73 million, a price-to-earnings ratio of -2.63 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The stock’s fifty day moving average price is $8.40 and its two-hundred day moving average price is $12.39. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). The company had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Arcus Biosciences’s revenue for the quarter was down 80.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) earnings per share.

Insiders Place Their Bets

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of the stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares of the company’s stock, valued at $285,704. The trade was a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Terry J. Rosen purchased 19,800 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were acquired at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Arcus Biosciences

Large investors have recently bought and sold shares of the business. Gilead Sciences Inc. bought a new position in Arcus Biosciences in the fourth quarter valued at approximately $447,610,000. Boxer Capital Management LLC bought a new stake in Arcus Biosciences in the 4th quarter valued at $23,857,000. Vanguard Group Inc. boosted its stake in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the period. Braidwell LP bought a new position in Arcus Biosciences during the 4th quarter worth about $11,943,000. Finally, Millennium Management LLC raised its stake in shares of Arcus Biosciences by 277.1% in the 4th quarter. Millennium Management LLC now owns 924,369 shares of the company’s stock valued at $13,764,000 after purchasing an additional 679,267 shares during the period. 92.89% of the stock is owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.